Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. - Wikidata - awgldk - TriplyDB

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.

http://www.wikidata.org/entity/Q37169655

about

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies Laquinimod treatment in the R6/2 mouse model.Investigational agents for the management of Huntington's disease.Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?Disclosing Huntington's Genetic Testing Results in the Context of Intellectual Disability and Guardianship: Using the Family Illness Narrative to Guide the Flow of Information.Laquinimod attenuates inflammation by modulating macrophage functions in traumatic brain injury mouse model.Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches

P2860

Q27316866-FDE60A8A-D6AF-4779-99B5-F55B8C63F9EA Q28072237-852B34B5-EFF6-49C1-B404-CB2BAB574E17 Q33890346-7B43E886-A319-4395-9247-05425314AF57 Q39031769-6323CA4F-240E-4C29-A4CE-9FB55FD3C579 Q45294338-415034E8-D1D9-4BDA-982B-5A4E3C609888 Q45298439-1B483D9E-1FD5-4AC9-914B-4AEF2FF0FCDC Q47695368-AB003D53-40A2-41D0-9E89-5AC33C795CB6 Q58737028-ECE20703-B02A-4906-BAB3-F974E6928E14

P2860

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.

http://www.wikidata.org/entity/Q37169655

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 January 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Laquinimod dampens hyperactive ...... disease patient myeloid cells.

@en

Laquinimod dampens hyperactive ...... disease patient myeloid cells.

@nl

type

label

Laquinimod dampens hyperactive ...... disease patient myeloid cells.

@en

Laquinimod dampens hyperactive ...... disease patient myeloid cells.

@nl

prefLabel

Laquinimod dampens hyperactive ...... disease patient myeloid cells.

@en

Laquinimod dampens hyperactive ...... disease patient myeloid cells.

@nl

P1433

Q37169655-E04357FA-08AA-4DE2-9F4C-1F93B84BFC84

P1476

Q37169655-42278D03-45DD-41C6-9FBB-D988606A5C11

P2093

Q37169655-1AB67AE1-9127-4A85-9B3F-CD1A54B6D68D

Q37169655-39F99056-D567-49CA-8527-D2B7915EB0B9

Q37169655-4F822B01-34D9-40E1-B9DA-511459FA4F4F

Q37169655-94F2E330-6D32-4AE0-BF01-5A72A14282B9

Q37169655-CD5B4D94-C69B-41A2-9805-BF36C572CDDB

P2860

Q37169655-0957C202-66BF-47DC-A1E1-31331F51D7F6

Q37169655-0F857E71-020D-4C3C-939D-8CD4E0593F2E

Q37169655-0F861BB6-9A8D-42B8-B122-06D939613F8A

Q37169655-193CC43E-FF8E-42A9-8156-E251770EE2A5

Q37169655-1A35F74E-72F6-4EDD-BB67-570AB48309D9

Q37169655-3029010C-4A82-4382-AE37-5A1172EFE68F

Q37169655-34E312E8-2296-4B6B-B5E7-F87B0C30D0AA

Q37169655-38814969-F403-42DA-8200-AD29AF2FE135

Q37169655-3DBE411F-36F2-4090-9BFA-AC2AEE5A329C

Q37169655-47A54F4F-C821-4C66-B486-962B9344F3C5

P304

Q37169655-3FACFB4F-4D2D-4DB8-BA95-1BA638D7823A

P31

Q37169655-478E8DFD-B70B-4DE7-A2F0-E89A89DAA3BE

P356

Q37169655-E91437C7-C5C1-4000-B083-747397F1E67E

P407

Q37169655-E19F8F3F-45F0-4210-8FBE-B401EC3BE441

P433

Q37169655-A5F7CC7C-2148-48E5-B6DD-53339FBF8DD0

P478

Q37169655-01D22734-53F2-45DC-8CD1-D6E0CBFCCC70

P50

Q37169655-91F93A69-96DB-46E0-9936-0F9D80FFE328

Q37169655-CE22639B-6C7B-46E6-86D6-F1557F60114D

P577

Q37169655-625C2042-A3CB-4BDA-B94F-35CF0C75E94F

P698

Q37169655-9EF3309C-3BFA-4B56-A641-8E9DCCE47366

P921

Q37169655-BE3F6F28-F263-41D4-A099-219714D791C6

Q37169655-C4E859B1-98C9-42D7-809B-FBCCE65A23F3

P932

Q37169655-027D4EEE-8973-4A63-A105-811DC822C0AF

P356

P1433

Journal of Neurochemistry

P1476

Laquinimod dampens hyperactive ...... disease patient myeloid cells.

@en

P2093

Liat Hayardeny

http://www.w3.org/2001/XMLSchema#string

Lucianne Dobson

http://www.w3.org/2001/XMLSchema#string

Pippa Loupe

http://www.w3.org/2001/XMLSchema#string

Ruth Farmer

http://www.w3.org/2001/XMLSchema#string

Ulrike Träger

http://www.w3.org/2001/XMLSchema#string

P2860

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

NF-κB, the first quarter-century: remarkable progress and outstanding questions

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

The M1 and M2 paradigm of macrophage activation: time for reassessment

Mutant huntingtin impairs immune cell migration in Huntington disease.

Oral laquinimod therapy in relapsing multiple sclerosis.

Huntington's disease: from molecular pathogenesis to clinical treatment.

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

P304

782-794

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JNC.13553

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Sarah J. Tabrizi

Michael R. Hayden

P577

2016-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26823290

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

4982105

http://www.w3.org/2001/XMLSchema#string